id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2195-0007,FDA,FDA-2022-E-2195,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:07:21Z,,0,0,09000064868c507b
FDA-2022-E-2195-0006,FDA,FDA-2022-E-2195,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2024-01-18T21:41:55Z,,0,0,09000064863a7cd9
FDA-2022-E-2195-0005,FDA,FDA-2022-E-2195,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-10T05:00:00Z,2024,1,2024-01-10T05:00:00Z,,2025-01-16T12:50:49Z,,0,0,090000648638ab18
FDA-2022-E-2195-0004,FDA,FDA-2022-E-2195,Determination of Regulatory Review Period for Purposes of Patent Extension; Tivdak,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T15:33:28Z,2023-26992,0,0,090000648631751c
FDA-2022-E-2195-0003,FDA,FDA-2022-E-2195,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-22T04:00:00Z,2022,9,2022-09-22T04:00:00Z,,2022-09-22T15:24:53Z,,0,0,09000064853502a9
FDA-2022-E-2195-0001,FDA,FDA-2022-E-2195,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-09-12T04:00:00Z,2022,9,2022-09-12T04:00:00Z,,2022-09-12T14:45:48Z,,0,0,09000064852e9fa1
FDA-2022-E-2195-0002,FDA,FDA-2022-E-2195,Patent Extension Application from Morrison & Foerster LLP,Other,Application,2022-09-12T04:00:00Z,2022,9,2022-09-12T04:00:00Z,,2022-09-12T14:46:08Z,,0,0,09000064852e9fa3